Tag Archives: Sarepta Therapeutics

October 11, 2020   No comments

Analysts’ Top Healthcare Picks: Sarepta Therapeutics (SRPT), Teladoc (TDOC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report) and Teladoc (TDOC – Research Report) with bullish sentiments. Sarepta Therapeutics (SRPT) RBC Capital analyst Brian

Read More
September 28, 2020   No comments

Analysts’ Top Healthcare Picks: Sarepta Therapeutics (SRPT), Johnson & Johnson (JNJ)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report), Johnson & Johnson (JNJ – Research Report) and Palatin Technologies (PTN – Research Report) with bullish

Read More
August 3, 2020   No comments

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT), Incyte (NASDAQ: INCY) and Lexicon Pharmaceuticals (NASDAQ: LXRX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Incyte (INCY – Research Report) and Lexicon Pharmaceuticals (LXRX – Research Report). Sarepta Therapeutics (SRPT) Credit Suisse

Read More
May 17, 2020   No comments

Nomura Remains a Buy on Sarepta Therapeutics (SRPT)

Nomura analyst Christopher Marai maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) on May 15 and set a price target of $230.00. The company’s shares closed last Friday at $141.25. According to TipRanks.com, Marai is a 4-star

Read More
May 16, 2020   No comments

A Director at Sarepta Therapeutics (NASDAQ: SRPT) is Selling Shares

Yesterday, a Director at Sarepta Therapeutics (SRPT – Research Report), Richard Barry, sold shares of SRPT for $4.24M. Following Richard Barry’s last SRPT Sell transaction on September 16, 2019, the stock climbed by 54.2%. This is Barry’s first Sell trade

Read More
May 15, 2020   No comments

Mizuho Securities Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $183.00. The company’s shares closed last Friday at $139.34. According to TipRanks.com, Yang has currently 0 stars

Read More
« Older posts